Skip to main content
. 2013 Jun 4;19(4):740–749. doi: 10.1007/s10156-013-0622-9

Table 1.

Demographic and baseline characteristics of participants included in the full analysis set index-infected virus-negative at baseline

Characteristic LO-2 (N = 487) LO-3 (N = 486) Placebo (N = 478) Characteristic LO-2 (N = 487) LO-3 (N = 486) Placebo (N = 478)
Participants Index patientsa
Age Age
Mean ± SD (years) 34.5 ± 9.7 33.8 ± 10.2 34.0 ± 9.2 Mean ± SD (years) 7.5 ± 3.5 7.5 ± 4.3 7.7 ± 5.3
Group (years) [no. (%)] Group (years) [no. (%)]
 10–14 43 (8.8) 58 (11.9) 43 (9.0)  0–4 98 (20.1) 96 (19.8) 89 (18.6)
 15–19 18 (3.7) 9 (1.9) 11 (2.3)  5–9 264 (54.2) 281 (57.8) 275 (57.5)
 20–29 36 (7.4) 37 (7.6) 42 (8.8)  10–14 116 (23.8) 97 (20.0) 99 (20.7)
 30–39 241 (49.5) 235 (48.4) 264 (55.2)  15–19 6 (1.2) 5 (1.0) 7 (1.5)
 40–49 144 (29.6) 141 (29.0) 113 (23.6)  20–29 3 (0.6) 4 (0.8) 3 (0.6)
 50–59 4 (0.8) 5 (1.0) 4 (0.8)  30–39 0 (0.0) 2 (0.4) 2 (0.4)
 60– 1 (0.2) 1 (0.2) 1 (0.2)  40–49 0 (0.0) 0 (0.0) 2 (0.4)
Sex [no. (%)]  50–59 0 (0.0) 1 (0.2) 0 (0.0)
 Female 427 (87.7) 423 (87.0) 422 (88.3)  60– 0 (0.0) 0 (0.0) 1 (0.2)
 Male 60 (12.3) 63 (13.0) 56 (11.7) Sex [no. (%)]
Time to first dose after onset in index patients  Female 238 (48.9) 236 (48.6) 219 (45.8)
Mean ± SD (h) 21.6 ± 11.3 23.0 ± 12.5 22.5 ± 12.6  Male 249 (51.1) 250 (51.4) 259 (54.2)
Group (h) [no. (%)] Rapid diagnostic test [no. (%)]
 0–12 101 (20.7) 101 (20.8) 99 (20.7)  Positive 487 (100.0) 486 (100.0) 478 (100.0)
 12–24 207 (42.5) 181 (37.2) 189 (39.5)  Laboratory-confirmed influenza infection
 24–36 122 (25.1) 123 (25.3) 117 (24.5) Virus Type and Subtype [no. (%)]
 36–48 54 (11.1) 80 (16.5) 70 (14.6)  2009H1N1 0 (0.0) 0 (0.0) 0 (0.0)
 48– 3 (0.6) 1 (0.2) 3 (0.6)  H1N1 0 (0.0) 0 (0.0) 0 (0.0)
Relationship to index patient [no. (%)]  H3N2 443 (91.0) 440 (90.5) 434 (90.8)
 Parent 423 (86.9) 413 (85.0) 415 (86.8)  B 43 (8.8) 44 (9.1) 43 (9.0)
 Sibling 62 (12.7) 69 (14.2) 54 (11.3)  Mixed 1 (0.2) 2 (0.4) 1 (0.2)
 Child 0 (0.0) 1 (0.2) 1 (0.2) Treatment of influenza [no. (%)]
 Spouse 1 (0.2) 0 (0.0) 3 (0.6)  Oseltamivir 373 (76.6) 389 (80.0) 372 (77.8)
 Other 1 (0.2) 3 (0.6) 5 (1.0)  Zanamivir 113 (23.2) 94 (19.3) 101 (21.1)
High-riskb [no. (%)] 14 (2.9) 10 (2.1) 20 (4.2)  Other 1 (0.2) 3 (0.6) 5 (1.0)

LO-2 20 mg of laninamivir octanoate administered once daily for 2 days, LO-3 20 mg of laninamivir octanoate administered once daily for 3 days, SD standard deviation, 2009H1N1 influenza A(H1N1)pdm09, H1N1 seasonal influenza A(H1N1), H3N2 influenza A(H3N2), B influenza B

aMore than one participant could be enrolled for each index patient. In this case, the index patient was counted once for each household contact who was enrolled. Actually, 1278 index patients (FASIINAB) were enrolled. In this table, the “N” is identical for household contacts and index patients in each treatment group. This is due to “reduplicative” counting

bAge ≥65 years or with concomitant illness (immunodeficiency, metabolic disorder, chronic respiratory illness, chronic renal impairment, or chronic heart disease)